TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00346047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo is applied for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System
Description: Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
Study: NCT00251303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched active drug in appearance.
Study: NCT03007290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Description: Therapeutic drug monitoring for colistin
Study: NCT04560283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal gel HYALOGYN®
Description: Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expectant management
Description: Expectant management for 12 consecutive weeks
Study: NCT00632684

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interviews with a single treatment planning session
Description: Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive treatment model
Description: The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
Study: NCT02429388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
Study: NCT00865917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta-blocker (Metoprolol)
Description: Metoprolol 95 mg once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I(f)-blocker (ivabradine)
Description: ivabradine 7.5 mg once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching appearance
Study: NCT00702442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: 0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution administrated i.v 30 min prior surgery
Study: NCT03030105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: placebo
Study: NCT00382590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Azacytidine
Description: 75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 20 mg twice daily via subcutaneous injection for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: 50 mg/m\^2 orally daily days 1-7.
Study: NCT03073694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
Study: NCT00591617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment plus Suboxone pharmacotherapy
Description: Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment plus Suboxone pharmacotherapy
Description: Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment plus Suboxone pharmacotherapy
Description: Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment plus Suboxone pharmacotherapy
Description: Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
Study: NCT04188015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5mg ANX007
Description: A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5.0mg ANX007
Description: A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
Study: NCT00559403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD Risk-Reduction
Description: Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
Study: NCT01122407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: L-NMMA 250 ug/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Will infuse trimethaphan for until complete autonomic blockade is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Will infuse trimethaphan for until complete autonomic blockade is achieved.
Study: NCT00834639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: delayed-release 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: delayed-release 500 mg tablet
Study: NCT03653351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
Study: NCT02814227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zansors® sleep screening device
Description: Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
Study: NCT00177307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
Study: NCT04346901

Intervention type: DRUG
Group type: OTHER
Intervention: Thiamazol
Description: All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
Study: NCT03030105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 MG/ML
Description: cognition impairment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine placebo
Description: placebo
Study: NCT01042145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 2 mgs/kg for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.6 mgs for one day, then placebo for 2 days
Study: NCT00003829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT00102648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02223650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overminus treatment
Description: 2.50D overminus spectacles
Study: NCT00493337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Card
Study: NCT01820533

Intervention type: OTHER
Intervention: Cell Phone Survey
Description: Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
Study: NCT04093141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRE
Description: in situ irreversible electroporation
Study: NCT02115997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
Study: NCT01676025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LA
Study: NCT03519698

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water
Description: Footbaths were prepared with 12 liters of warm water (40 °C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Footbaths were prepared with 12 liters of warm water (40 °C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Footbaths were prepared with 12 liters of warm water (40 °C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mustard
Description: 12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger
Description: 12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
Study: NCT03343405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mind/Body Program for Fertility
Description: The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
Study: NCT03499626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD
Study: NCT01465503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated Heparin
Description: Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
Study: NCT02223650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-overminus treatment
Description: spectacles without overminus or no spectacles
Study: NCT03376451

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of endometrium and blood biomarkers for endometriosis diagnosis
Description: Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
Study: NCT03760367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue covarine toothpaste
Description: 2 min toothbrushing with 1 g of Pepsodent White Now Gold

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control toothpaste
Description: 2 min toothbrushing with 1 g of Colgate Advanced Whitening
Study: NCT00962975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
Study: NCT00862342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
Study: NCT01828541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Patients in this group will receive standard care plus 4 sessions of hypnosis.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study: NCT04501978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Provided to all study participants as SOC unless contraindicated for an individual patient.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Provided to all study participants as SOC unless contraindicated for an individual patient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831
Description: Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-196/BRII-198
Description: Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0420
Description: Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: 250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
Study: NCT03087422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message intervention
Description: The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
Study: NCT03737500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Lite® light weight breast implant
Description: Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard silicone-based breast implant
Description: Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
Study: NCT01609634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Product
Description: Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
Study: NCT05360342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K supplement
Description: Single dose of vitamin K supplement
Study: NCT03467997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trier social stress test
Description: Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trier social stress test
Description: Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel exhaust
Description: Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel exhaust
Description: Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
Study: NCT05122052

Intervention type: OTHER
Intervention: Psychological session
Description: Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
Study: NCT01609634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product 1
Description: Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product 2
Description: Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.